Reports Q4 revenue $528.2M, consensus $479.7M. "We delivered total revenue of nearly $2 billion in 2022, reflecting 25 percent growth compared to 2021 driven by strong demand for our portfolio of approved products," said David Epstein, Chief Executive Officer of Seagen. "We made excellent progress in growing our four marketed brands. Importantly, the FDA is currently reviewing our supplemental regulatory submission under the accelerated approval program for PADCEV as first-line treatment for cisplatin-ineligible patients with advanced urothelial cancer, which has the potential to be a meaningful growth driver for the brand. We anticipate multiple key data and regulatory catalysts in 2023, which will provide a path for us to build a more global oncology leader with the potential to address the needs of still larger populations of cancer patients."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Cellectar Biosciences hires Shustov as new Senior Vice President, Medical
- Seagen treatment of esophageal cancer granted orphan designation
- 3 Stocks to Buy Today, 2/13/2023, According to Top Analysts
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- SVB Securities downgrades Seagen to Market Perform, lowers price target to $141